|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
361,116 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bonstein Sara |
Chief Financial Officer |
|
2014-08-01 |
4 |
D |
$2.84 |
$406 |
D/D |
(143) |
84,597 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2014-08-01 |
4 |
A |
$2.84 |
$1,945 |
D/D |
685 |
84,740 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2014-08-01 |
4 |
D |
$2.84 |
$315 |
D/D |
(111) |
134,990 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2014-08-01 |
4 |
A |
$2.84 |
$2,292 |
D/D |
807 |
135,101 |
|
- |
|
French Christy Lee |
VP-Regulatory, Medical Affairs |
|
2014-08-01 |
4 |
D |
$2.84 |
$8,051 |
D/D |
(2,011) |
73,005 |
|
- |
|
French Christy Lee |
VP-Regulatory, Medical Affairs |
|
2014-08-01 |
4 |
A |
$2.84 |
$1,204 |
D/D |
424 |
73,050 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-08-01 |
4 |
D |
$2.84 |
$34,018 |
D/D |
(8,699) |
296,439 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-08-01 |
4 |
A |
$2.84 |
$9,375 |
D/D |
3,301 |
297,312 |
|
- |
|
Appel Roni |
Director |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
117,331 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2014-07-17 |
4 |
D |
$5.07 |
$86,438 |
D/D |
(17,049) |
84,055 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
101,104 |
|
- |
|
Sidransky David |
Director |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
60,304 |
|
- |
|
Patton James P |
Director |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
158,528 |
|
- |
|
Mckearn Thomas J |
Director |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
73,529 |
|
- |
|
Berman Richard J |
Director |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Moore Thomas A |
Former Director |
|
2014-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,976 |
176,462 |
|
- |
|
French Christy Lee |
VP-Regulatory, Medical Affairs |
|
2014-07-17 |
4 |
D |
$4.03 |
$18,175 |
D/D |
(4,510) |
74,592 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2014-07-17 |
4 |
D |
$4.03 |
$22,487 |
D/D |
(5,580) |
114,303 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-07-17 |
4 |
D |
$4.03 |
$66,366 |
D/D |
(16,468) |
301,837 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-07-01 |
4 |
D |
$3.15 |
$3,774 |
D/D |
(1,198) |
318,305 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,968 |
319,503 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2014-07-01 |
4 |
D |
$3.15 |
$466 |
D/D |
(148) |
134,294 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
971 |
134,442 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2014-07-01 |
4 |
D |
$3.15 |
$762 |
D/D |
(242) |
1,104 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
824 |
1,346 |
|
- |
|
586 Records found
|
|
Page 18 of 24 |
|
|